https://www.selleckchem.com/products/bay-293.html
Combination therapy with anti-PD-1 and ATRA improved local and systemic T-cell proliferation and generated tumor-specific immunity. Our findings implicate ELR+ CXC chemokine-mediated enrichment of G-MDSCs as a potential mediator of immunosuppression in LKB1-deficient NSCLC and provide a rationale for using ATRA in combination with anti-PD-1 therapy in patients with LKB1-deficient NSCLC refractory to ICIs. SIGNIFICANCE These findings show that accumulation of myeloid-derived suppressor cells in LKB1-deficient non-small cell lung cancer c
Mi piace
Commento
Condividi
